Patent
Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
| العنوان: | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
|---|---|
| Patent Number: | 8,536,184 |
| تاريخ النشر: | September 17, 2013 |
| Appl. No: | 12/622411 |
| Application Filed: | November 19, 2009 |
| مستخلص: | The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products produced by the process, and salts or prodrugs thereof. The invention further provides a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases comprising administering an effective amount of a compound according to the invention to a patient in need thereof. |
| Inventors: | Kanter, James (South San Francisco, CA, US); Robinson, James (Sacramento, CA, US); Pandey, Anjali (Fremont, CA, US); Scarborough, Robert M. (Half Moon Bay, CA, US) |
| Assignees: | Millennium Pharmaceuticals, Inc. (Cambridge, MA, US) |
| Claim: | 1. A compound having the formula: [chemical expression included] and salts thereof. |
| Claim: | 2. A compound having the formula: [chemical expression included] |
| Current U.S. Class: | 51425/501 |
| Patent References Cited: | 3800039 March 1974 Marquis 4607034 August 1986 Mizogami et al. 4797419 January 1989 Moos et al. 4983606 January 1991 Casagrande et al. 5120843 June 1992 McCall et al. 5446062 August 1995 Dellaria et al. 5457105 October 1995 Barker 5576333 November 1996 Miller 5591883 January 1997 Hwang et al. 5747498 May 1998 Schnur 5770599 June 1998 Gibson 5821246 October 1998 Brown et al. 5962458 October 1999 Thomas et al. 6004967 December 1999 McMahon et al. 6071921 June 2000 Thomas et al. 6169088 January 2001 Matsuno et al. 6184225 February 2001 Thomas et al. 6207667 March 2001 Matsuno et al. 6258951 July 2001 Thomas et al. 6265411 July 2001 Thomas et al. 6291455 September 2001 Thomas et al. 6294532 September 2001 Thomas et al. 6362336 March 2002 Lohmann et al. 6414148 July 2002 Thomas et al. 6423716 July 2002 Matsuno et al. 6472391 October 2002 Matsuno et al. 6593333 July 2003 Cumming 6716847 April 2004 Cumming 6750218 June 2004 Matsuno et al. 6806274 October 2004 Crawley et al. 6897210 May 2005 Thomas et al. 6900221 May 2005 Connell et al. 6982266 January 2006 Pandey et al. 7138413 November 2006 Schwartz et al. 7232903 June 2007 Nishino et al. 7253164 August 2007 Molteni et al. 7309716 December 2007 Wilson et al. 7329755 February 2008 Dai et al. 7368457 May 2008 Josien 7378525 May 2008 Dai et al. 7709640 May 2010 Kanter et al. 2002/0068734 June 2002 Matsuno et al. 2003/0100573 May 2003 Wang et al. 2003/0187053 October 2003 Bertinato et al. 2004/0067981 April 2004 Koyama et al. 2005/0070560 March 2005 Himmelsbach et al. 2005/0080262 April 2005 Nishino et al. 2005/0124809 June 2005 Nishino et al. 2005/0130995 June 2005 Nishino et al. 2005/0239777 October 2005 Thomas et al. 2006/0004017 January 2006 Stokes et al. 2007/0037793 February 2007 Koyama et al. 2007/0037795 February 2007 Koyama et al. 0 454 498 October 1991 0 535 925 April 1993 0 535 926 April 1993 0 617 001 September 1994 0 709 363 May 1996 0 790 986 May 1996 0 823 419 February 1998 0 882 717 December 1998 1 067 123 January 2001 1 086 078 February 2003 1 466 907 October 2004 1 154 774 June 2005 1 553 097 July 2005 S58-172379 October 1983 5-208911 August 1993 6-247942 September 1994 H6-247942 September 1994 11-80131 March 1999 S60-120872 June 2005 WO 88/08424 November 1988 WO 92/20642 November 1992 WO 94/00444 January 1994 WO 94/12181 June 1994 WO 94/22834 October 1994 WO 95/14017 May 1995 WO 96/08486 March 1996 WO 96/09294 March 1996 WO 96/09818 April 1996 WO 96/15118 May 1996 WO 96/17833 June 1996 WO 96/30347 October 1996 WO 97/01569 January 1997 WO 97/03069 January 1997 WO 97/06802 February 1997 WO 97/12615 April 1997 WO 97/14685 April 1997 WO 97/22596 June 1997 WO 97/27746 August 1997 WO 97/28139 August 1997 WO 97/28141 August 1997 WO 97/30035 August 1997 WO 97/32856 September 1997 WO 97/42187 November 1997 WO 97/46562 December 1997 WO 95/10767 March 1998 WO 98/13354 April 1998 WO 98/31675 July 1998 WO 98/35959 August 1998 WO 98/14431 September 1998 WO 99/10349 March 1999 WO 99/16751 April 1999 WO 99/18096 April 1999 WO 99/51582 October 1999 WO 99/61410 December 1999 WO 99/84394 December 1999 WO 00/06254 February 2000 WO 00/20402 April 2000 WO 00/21955 April 2000 WO 00/39118 July 2000 WO 00/43326 July 2000 WO 00/47212 August 2000 WO 00/55141 September 2000 WO 01/04102 January 2001 WO 01/21594 March 2001 WO 01/21595 March 2001 WO 01/21596 March 2001 WO 01/21597 March 2001 WO 01/34574 May 2001 WO 01/66099 September 2001 WO 01/77085 October 2001 WO 01/94341 December 2001 WO 02/00644 January 2002 WO 02/02534 January 2002 WO 02/16352 February 2002 WO 02/16360 February 2002 WO 02/16361 February 2002 WO 02/16362 February 2002 WO 02/18372 March 2002 WO 02/30924 April 2002 WO 02/30926 April 2002 WO 02/34744 May 2002 WO 02/36587 May 2002 WO 02/059074 August 2002 WO 02/070509 September 2002 WO 02/072578 September 2002 WO 02/085895 October 2002 WO 02/067587 November 2002 WO 02/092577 November 2002 WO 02/092578 November 2002 WO 02/092579 November 2002 WO 03/045364 June 2003 WO 03/045943 June 2003 WO 03/054819 July 2003 WO 03/055491 July 2003 WO 03/064399 August 2003 WO 03/066602 August 2003 WO 2004/026829 April 2004 WO 2004/033441 April 2004 WO 2004/033463 April 2004 WO 2004/056809 July 2004 WO 2004/089918 October 2004 WO 2004/085418 January 2005 6706512 October 1967 |
| Other References: | US 5,616,682, 04/1997, Barker (withdrawn) cited by applicant Abstracts of the 116th Annual Meeting of the Pharmaceutical Society of Japan, Kanazawa, 2:275; 29(c2):15-21 (1996). cited by applicant Agrawal, Vijai, et al. “Antiparasitic agents. Part VI: Synthesis of 7-chloro-4-(4-substituted-phenylanino)- and 7-chloro-4-(4-substituted-piperazin-1-yl) quinolines as potential antiparasitic agents” Indian J. Chem., Sect. B (1987), 26(B) 6 pp. 550-555. cited by applicant Anderson, K, et al. “Oxadiazoles as bioisosteric transformations of carboxylic functionalities,” Eur. J. Med. Chem 31:417-425 (1996). cited by applicant Chen, S. et al., “Putative benzodiazepine partial agonists demonstrate receptor heterogeneity” Pharmacology Biochemistry and Behavior 53(1):87-97 (1996). cited by applicant Griswold, Ian, et al. “Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis,” Blood, 2004, vol. 104, No. 9, pp. 2912-2918. cited by applicant Kelly, Louise, et al. “CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML),” Cancer Cell, 2002, vol. 1, pp. 421-432. cited by applicant Kovalenko, M. et al., “Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation” Cancer Research 54:6106-6114 (1994). cited by applicant LeMahieu, Ra, et al., “(E)-3-(4-Oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents.” J. Med. Chem., 1983, vol. 26, No. 3, pp. 420-425. cited by applicant Matsuno et al., “Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 1. Synthesis, Structure-Activity Relationship, and Biological Effects of a New Class of Quinazoline Derivatives.” Journal of Medicinal Chemistry, vol. 45, No. 14, pp. 3057-3066, 2002. cited by applicant Pandey, Anjali, et al. “Identification of Orally Active, Potent and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family,” J. Med. Chem., 2002, vol. 45, pp. 3772-3793. cited by applicant Patent Abstracts of Japan vol. 18, No. 639, Dec. 6, 1994 & JP 06 247942 A (Kyowa Hakko Kogyo Co., Ltd.), Sep. 6, 1994 (Abstract). cited by applicant Patent Abstracts of Japan vol. 8, No. 3, Jan. 7, 1984 & JP 58 172379 A (Showa Denko KK), Oct. 11, 1983 (Abstract). cited by applicant Patent Abstracts of Japan vol. 9, No. 271, Oct. 29, 1985 & JP 60 120872 A (Kyowa Hakko Kogyo Co., Ltd.) Jun. 28, 1985 (Abstract). cited by applicant Robinson et al., “Novel inhibitors of procollagen C-Proteinase. Part 2: glutamic acid hydroxamates.” Bioorganic & Medicinal Chemistry Letters, vol. 13, No. 14, pp. 2381-2381, 2003. cited by applicant |
| Primary Examiner: | Ward, Paul V. |
| Attorney, Agent or Firm: | Kilpatrick Townsend & Stockton LLP |
| رقم الانضمام: | edspgr.08536184 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |